Haemophilia care - beyond the treatment guidelines

Haemophilia

Volumn 20, Issue S4, 2014, Pages 4-10

  Srivastava, A ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Assessment; Doses; Haemophilia; Optimal; Outcomes; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING FACTOR;

BRAZIL; CLINICAL ASSESSMENT; ENVIRONMENTAL FACTOR; FUNCTIONAL STATUS; HEALTH CARE ACCESS; HEMARTHROSIS; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; JOINT RADIOGRAPHY; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RUSSIAN FEDERATION; SOUTH AFRICA; SUBSTITUTION THERAPY; SWEDEN; UNITED KINGDOM; UNITED STATES; HEMOPHILIA A; TREATMENT OUTCOME;

BLOOD COAGULATION FACTORS; HEMOPHILIA A; HUMANS; PATIENT OUTCOME ASSESSMENT; TREATMENT OUTCOME;

EID: 84899526089     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12429     Document Type: Review

References (63)

1. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
3. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
4. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-48.
5. Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-50.
6. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16 Suppl 5: 181-8.
7. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003; 9 Suppl 1: 10-7; discussion 8.
8. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
9. Srivastava A, You SK, Ayob Y et al. Hemophilia treatment in developing countries: products and protocols. Semin Thromb Hemost 2005; 31: 495-500.
10. Auerswald G, Salek SZ, Benson G et al. Beyond patient benefit: clinical development in hemophilia. Hematology 2012; 17: 1-8.
11. Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18: 568-74.
12. Meunier S, Chambost H, Demiguel V, Doncarli A, Suzan F, Trossaert M. Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit. J Pediatr; 162: 1241-4, 4 e1.
13. Ono O, Suzuki Y, Yosikawa K et al. Assessment of haemophilia treatment practice pattern in Japan. Haemophilia 2009; 15: 1032-8.
14. Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19 Suppl 1: 2-7.
15. Pratt KP. Inhibitory antibodies in hemophilia A. Curr Opin Hematol; 19: 399-405.
16. Gouw SC, van dBJ, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med; 368: 231-9.
17. ter Avest PC, Fischer K, Mancuso ME et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
18. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
19. Gringeri A, Lundin B, von MS, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost; 9: 700-10.
20. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
21. Hilliard P, Zourikian N, Blanchette V et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013; 11: 460-6.
22. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19: e239-47.
23. Fischer K, Hermans C. The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013; 19: 35-43.
24. http://www.ukhcdo.org/docs/AnnualReports/2012/1UK%20National%20Haemophilia%20Database%20Bleeding%20Disorder%20Statistics%202011-2012%20for%20website.pdf. Accessed March 22, 2014.
25. Fischer K, Steen CK, Petrini P et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36.
26. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
27. http://www1.wfh.org/publications/files/pdf-1574.pdf. Accessed March 22, 2014.
28. Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005; 31: 507-12.
29. Skinner MW. WFH: closing the global gap-achieving optimal care. Haemophilia 2012; 18 Suppl 4: 1-12.
30. Srivastava A. Dose and response in haemophilia-optimization of factor replacement therapy. Br J Haematol 2004; 127: 12-25.
31. Aznar JA, Marco A, Jimenez-Yuste V et al. Is on-demand treatment effective in patients with severe haemophilia? Haemophilia 2012; 18: 738-42.
32. Ozelo MC, Villaca PR, Perez-Bianco R et al. Musculoskeletal evaluation in severe haemophilia A patients from Latin America. Haemophilia 2014; 20: e63-70.
33. www.musfih.net.
34. Mahlangu JN. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia 2009; 15: 135-41.
35. Ozelo MC, Matta MA, Yang R. Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia 2012; 18 Suppl 5: 33-8.
36. Tang L, Wu R, Sun J et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 2013; 19: 27-34.
37. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
38. Poonnoose P, Keshava S, Gibikote S, Feldman BM. Outcome assessment and limitations. Haemophilia 2012; 18 Suppl 4: 125-30.
39. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost 2012; 10: 2223-9.
40. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken); 63: 223-30.
41. de MP, Fischer K, Lambert T et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia; 18: 319-25.
42. Feldman BM. Implementing musculoskeletal outcome assessments in clinical practice. Haemophilia 2012; 18 Suppl 4: 120-4.
43. Lundin B, Manco-Johnson ML, Ignas DM et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18: 962-70.
44. Doria A. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy. MRI correlation. Am J Radiol 2014. (accepted).
45. Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia 2009; 15: 1168-71.
46. van Genderen FR, Westers P, Heijnen L et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12: 36-46.
47. Groen WG, van der NJ, Helders PJ, Fischer K. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (pedhal). Haemophilia 2010; 16: 281-9.
48. Brodin E, Baghaei F, Elfvinger P, Lindvall K, Sunnerhagen KS. The Swedish version of the Haemophilia Activity List. Haemophilia 2011; 17: 662-8.
49. Poonnoose PM, Thomas R, Keshava SN et al. Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). Haemophilia 2007; 13: 620-6.
50. Hassan TH, Badr MA, El-Gerby KM. Correlation between musculoskeletal function and radiological joint scores in haemophilia A adolescents. Haemophilia 2011; 17: 920-5.
51. Kachooei AR, Badiei Z, Zandinezhad ME et al. Influencing factors on the functional level of haemophilic patients assessed by FISH. Haemophilia 2014; 20: 185-9.
52. Tlacuilo-Parra A, Villela-Rodriguez J, Garibaldi-Covarrubias R, Soto-Padilla J, Orozco-Alcala J. Functional independence score in hemophiliazr: a cross-sectional study assessment of Mexican children. Pediatr Blood Cancer 2010; 54: 394-7.
53. Gonzalez LM, Peiro-Velert C, Devis-Devis J et al. Comparison of physical activity and sedentary behaviours between young haemophilia A patients and healthy adolescents. Haemophilia 2011; 17: 676-82.
54. Gringeri A, Von Mackensen S. Quality of life in haemophilia. Haemophilia 2008; 14(Suppl 3): 19-25.
55. Villaca PR, Carneiro JD, D'Amico EA et al. Process and experience of cross-cultural adaptation of a quality of life measure (CHO-KLAT) for boys with haemophilia in Brazil. Haemophilia 2013; 19: 861-5.
56. von MS, Campos IG, Acquadro C, Strandberg-Larsen M. Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents. Haemophilia; 19: e73-83.
57. Buchbinder D, Ragni MV. What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia? Hematology Am Soc Hematol Educ Program 2013; 52-5.
58. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
59. Blanchette VSKN, Lung LR, Manco-Johnson MJ, Van DBH, Srivastava A. Definitions in hemophilia: a report from the project group of the FVIII/IX subcommittee of the International Society on Thrombosis and Hemostasis. J Thromb Haemost 2014. (in press).
60. http://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/projects/2012_clinical_trials.pdf. Accessed March 22, 2014.
61. http://www.pednet.nl/registry. Accessed March 22, 2014.
62. http://www.cdc.gov/ncbddd/blooddisorders/udc/udc-hemophilia.html. Accessed March 22, 2014.
63. http://www.euhass.org. Accessed March 22, 2014.